Status:
COMPLETED
Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborating Sponsors:
ASST Santi Paolo e Carlo
Asst Melegnano e Martesana
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
We will conduct an observational study involving a preliminary long-term follow-up designed to test how dysbindin-1 gene expression can modulate the efficacy of treatments with antipsychotics on clini...
Detailed Description
During the first visit, all subjects will sign informed consent and undergo a a clinical interview, in which clinical data will be collected. The demographic information will be transcribed into the e...
Eligibility Criteria
Inclusion
- DB diagnoses, made by the use of the structured clinical interview based on the DSM-5 criteria (SCID-CV);
- Therapy with an atypical antipsychotic (aripiprazole or quetiapine or olanzapine) in combination with a mood stabilizer (lithium or another mood stabilizer mood), according to the standard of care.
Exclusion
- Comorbidity with other psychiatric disorders;
- comorbidity with neurological disorders, with damage to the brain and with deficits intellectual;
- pregnancy;
- current and past substance abuse.
Key Trial Info
Start Date :
November 8 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 8 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06167577
Start Date
November 8 2018
End Date
November 8 2023
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan, MI, Italy, 20100